RxDoctor Payments DataLook up a doctor →

Leonardo Gan-Lim, MD

Geriatric Medicine · Las Vegas, NVNPI 1134180839

Payments from drug & device makers

$10,309in general payments, 2019–2025

Across 430 payments — averaging $23.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Lilly USA, LLC$811
  • Novo Nordisk$674
  • Boehringer Ingelheim$595
  • Amgen$576
  • plus $5K from 40 others

What the payments were for

  • Consulting fees$1,20012%
  • Food & beverage$8,77185%
  • Education$3373%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,309 in reported general payments places this provider in the 95th percentile of 36 geriatric medicine providers in Nevada.

See all geriatric medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$139,384
Medicare patients
184
Services billed
1,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide190$202,581
JardianceEmpagliflozin116$134,510
EliquisApixaban96$85,678
FarxigaDapagliflozin Propanediol70$81,212
OzempicSemaglutide18$29,191
VascepaIcosapent Ethyl27$18,856
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$17,531
Repatha SureclickEvolocumab25$17,392
XareltoRivaroxaban19$14,942
MyrbetriqMirabegron13$13,316
TrulicityDulaglutide11$12,238
LinzessLinaclotide11$6,281
Praluent PenAlirocumab11$6,112
Atorvastatin Calcium276$3,060
Testosterone14$2,859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$811$214,819201 claims
Boehringer IngelheimJardiance$595$134,510116 claims
PfizerEliquis, Paxlovid$356$88,536126 claims
AstraZenecaFarxiga$1,444$81,21270 claims
Novo NordiskOzempic$674$29,19118 claims
GSKTrelegy Ellipta$111$17,53117 claims
Johnson & JohnsonXarelto$374$14,94219 claims
Astellas Pharma US IncMyrbetriq$355$13,31613 claims
AbbVieLinzess$449$6,28111 claims
Almatica Pharma LLCSertraline Hcl$67$62951 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 36 geriatric medicine providers in Nevada.

Other geriatric medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →